David Mangelsdorf and colleagues show that nuclear receptor expression is strongly associated with clinical outcomes of lung cancer patients, and this expression profile is a potential prognostic signature for lung cancer patient survival time, particularly for individuals with early stage disease.

Funding: This work was funded by the Howard Hughes Medical Institute (DJM), Cancer Prevention and Research Institute of Texas grant RP101251 (JDM and DJM); National Institutes of Health grants U19 DK62434 (DJM), P50 CA70907 (IIW, JDM, DJM), UL1 RR024982 (GX and YX), and CA152301 (YX); a Robert A. Welch Foundation grant I-1275 (DJM); the Gillson Longenbaugh Foundation (JDM); DOD VITAL and PROSPECT (IIW, JDM); and a National Center for Research Resources grant for the North and Central Texas Clinical and Translational Science Initiative (UL1RR024982 to YJ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

Citation: Jeong Y, Xie Y, Xiao G, Behrens C, Girard L, et al. (2010) Nuclear Receptor Expression Defines a Set of Prognostic Biomarkers for Lung Cancer. PLoS Med 7(12): e1000378. doi:10.1371/journal.pmed.1000378

Source:
PLoS Medicine